CEO: Thomas Olin
Description: Kancera develops new therapeutics, starting with a biological discovery and ending with an effective and safe drug candidate ready for clinical trials. Kancera focuses on the development of drug candidates with potential to combat therapy resistance and relapse in cancer. In addition, Kancera develops humanized cancer models for the evaluation of drug candidates and biomarkers. The wholly owned subsidiary iNovacia provides analytical development, screening, medicinal chemistry and ADME resources for the development of chemical probes and drug candidates to both academia and life science companies. We have partners and customers in Europe, the US and in South America.